Ethyl Cellulose Patents (Class 424/495)
-
Patent number: 8268804Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.Type: GrantFiled: September 3, 2010Date of Patent: September 18, 2012Assignee: Medicis Pharmaceutical CorporationInventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
-
Publication number: 20120231085Abstract: The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid.Type: ApplicationFiled: May 21, 2012Publication date: September 13, 2012Inventors: Likan Liang, Niraj Shah, Padmanabh P. Bhatt, Scott Ibrahim
-
Patent number: 8252776Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.Type: GrantFiled: April 2, 2007Date of Patent: August 28, 2012Assignee: Medicis Pharmaceutical CorporationInventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
-
Publication number: 20120201894Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.Type: ApplicationFiled: April 17, 2012Publication date: August 9, 2012Applicant: THERAVIDA, INC.Inventors: Mehdi PABORJI, Robert V. TUOHY, III, Peter R.P. FREED, Roger S. FLUGEL
-
Publication number: 20120189696Abstract: A coating film comprising ethyl cellulose as a component A and an (ethyl acrylate)-(methyl methacrylate) copolymer or a plasticized vinyl acetate polymer as a component B, and having a tensile elongation of 150% or more and a tensile strength of 9 N or more.Type: ApplicationFiled: October 6, 2010Publication date: July 26, 2012Applicant: ASAHI KASEI CHEMICALS CORPORATIONInventors: Naoya Yoshida, Kazuhiro Obae
-
Publication number: 20120171297Abstract: The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations.Type: ApplicationFiled: March 13, 2012Publication date: July 5, 2012Inventors: Stephen Peroutka, James Swarbrick
-
Publication number: 20120135082Abstract: The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with polymeric layer which enables the controlled release of the Venlafaxine Hydrochloride.Type: ApplicationFiled: November 21, 2011Publication date: May 31, 2012Applicant: LYCORED BIO LTD.Inventor: YORAM SELA
-
Publication number: 20120128771Abstract: A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating. Each Timed Pulsatile Release (TPR) bead population exhibits pre-determined lag-time followed by differing release characteristics. The composition and thickness of the barrier coating, composition and thickness of the lag-time coating, ratio of IR beads to one or more TPR bead populations and total dose may be varied depending on the alkalinity, pH-dependent solubility and elimination half-life of the active ingredients to achieve target PK profiles (suitable for a once or twice daily dosing regimen) in patients in need of such medications.Type: ApplicationFiled: July 19, 2011Publication date: May 24, 2012Inventor: Gopi M. Venkatesh
-
Patent number: 8182839Abstract: The present invention relates to novel nanoparticles based on cellulose and a process for producing them and their use.Type: GrantFiled: November 29, 2007Date of Patent: May 22, 2012Assignee: Dow Global Technologies LLCInventors: Jurgen Engelhardt, Birgit Kosan, Christa Maria Kruger, Frank Meister, Klaus Nachtkamp, Jens Schaller
-
Publication number: 20120100221Abstract: This invention relates to a layered pharmaceutical composition comprising a combination of an antihistamine and a decongestant.Type: ApplicationFiled: May 31, 2010Publication date: April 26, 2012Applicant: RANBAXY LABORATORIES LIMITEDInventors: Anuj Kumar Fanda, Kumaravel Vivek, Romi Barat Singh
-
Publication number: 20120093938Abstract: The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and/or a saccharide. These compositions are useful in treating the symptoms of one or more diseases or conditions in which diphenhydramine (alone or in combination with one or two other drugs) is a therapeutically effective, e.g. allergic rhinitis, sinusitis, upper respiratory tract infections, motion sickness, Parkinson's disease, insomnia, the common cold, and nighttime pain management, particularly for subjects or patients with dysphagia, and people ‘on the move’.Type: ApplicationFiled: July 14, 2011Publication date: April 19, 2012Applicant: EURAND INC.Inventors: Gopi M. VENKATESH, Jin-Wang LAI, Phillip PERCEL, Craig KRAMER
-
Publication number: 20120076865Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.Type: ApplicationFiled: March 24, 2011Publication date: March 29, 2012Applicant: JAZZ PHARMACEUTICALS, INC.Inventors: Clark Allphin, James Pfeiffer
-
Publication number: 20120064168Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.Type: ApplicationFiled: November 21, 2011Publication date: March 15, 2012Applicant: DEPOMED, INC.Inventors: BRET BERNER, SUI YUEN EDDIE HOU
-
Publication number: 20120045508Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.Type: ApplicationFiled: April 9, 2010Publication date: February 23, 2012Applicant: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Publication number: 20120040008Abstract: Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with NMT 70% in one hour, NMT 85% in 4 hour, and NLT 80% in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment-Resistant Depression (TRD) and Fragile X Syndrome.Type: ApplicationFiled: August 4, 2011Publication date: February 16, 2012Inventors: Ashish Chatterji, Jingjun Huang, Stephanie Koennings, Kai Lindenstruth, Harpreet Sandhu, Navnit Shah
-
Patent number: 8088414Abstract: A composition comprising: (i) at least one latex or pseudolatex water insoluble film former, (ii) at least one permeation enhancing agent and, optionally, (iii) one or more plasticizers. The present invention is also directed to substrates coated with the composition of the invention, films made from the composition and methods for making and using such compositions, coated substrates and films.Type: GrantFiled: January 31, 2007Date of Patent: January 3, 2012Assignee: FMC CorporationInventors: Juergen Siepmann, Florence Siepmann, Brian A. C. Carlin, Jian-Xin Li
-
Publication number: 20110311626Abstract: The present invention provides compositions comprising dicyclomine, or salts, and/or solvates and methods of making and using the compositions to treat intestinal hypermotility or Irritable Bowel Syndrome (IBS). The present invention also provides once-a-day orally disintegrating dosage forms comprising compositions of the present invention.Type: ApplicationFiled: February 23, 2010Publication date: December 22, 2011Inventors: Gopi Venkatesh, Vincent Parrino, Paolo Gatti, Flavio Fabiani
-
Publication number: 20110300224Abstract: A taste masked dosage form of pharmaceutical acceptable salt of escitalopram comprising (a) resin complex of pharmaceutical acceptable salt of escitalopram and cationic exchange resin or adsorbing or coating non-pareil seeds or inert particles with a mixture of pharmaceutically acceptable salt of escitalopram, cationic polymer and optionally other polymer(s) or loading non-pareil seeds or inert particles with pharmaceutically salt of escitalopram followed by polymer coating with cationic polymer and optionally other polymer(s); and (b) at least one pharmaceutical excipient.Type: ApplicationFiled: December 11, 2009Publication date: December 8, 2011Applicant: GENEPHARM A.E.Inventors: Deepak Murpani, Alexaki Pandora
-
Publication number: 20110287099Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.Type: ApplicationFiled: December 17, 2010Publication date: November 24, 2011Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
-
Publication number: 20110280939Abstract: The present invention relates to an oral particle including pseudoephedrine hydrochloride and cetirizine dihydrochloride, which primarily includes a nucleus having a diameter ranging 25˜40 mesh, a pseudoephedrine-hydrochloride layer coated outside the nucleus with a coating solution composed of pseudoephedrine hydrochloride, a binder, a lubricant and pure water/alcohol, a release-control layer coated outside the pseudoephedrine-hydrochloride layer, and a cetirizine-dihydrochloride layer coated outside the release-control layer with a coating solution composed of cetirizine dihydrochloride, a binder, a lubricant and pure water/alcohol. Accordingly, by distributing pseudoephedrine hydrochloride and cetirizine dihydrochloride into hundreds of the particles and controlling the dissolution rate with the release-control layer, the particles can perform good absorption efficiency, and quick, stable and long-term edicinal effect.Type: ApplicationFiled: July 5, 2011Publication date: November 17, 2011Applicant: EVEREST PHARM. INDUSTRIAL CO., LTD.Inventor: TA-PING LIAO
-
Publication number: 20110274762Abstract: The present invention relates to a pharmaceutical composition comprising Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation made of granules containing the active ingredient in their inner core.Type: ApplicationFiled: November 17, 2009Publication date: November 10, 2011Applicant: UCB PHARMA, S.A.Inventors: Domenico Fanara, Frederic Eeckman, Monique Berwaer
-
Publication number: 20110250282Abstract: The present invention relates to a pharmaceutical composition comprising Levetiracetam, Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation.Type: ApplicationFiled: November 17, 2009Publication date: October 13, 2011Applicant: UCB PHARMA, S.A.Inventors: Domenico Fanara, Frédéric Eeckman, Monique Berwaer
-
Publication number: 20110250281Abstract: The present invention provides a pharmaceutical composition comprising taste-masked immediate release microcapsules which comprise fexofenadine and a water-insoluble polymer coating. These microcapsules and the pharmaceutical compositions comprising them have suitable drug content and desirable pharmaceutical properties, including a quick dissolution rate of fexofenadine combined with a taste masking effect.Type: ApplicationFiled: December 2, 2010Publication date: October 13, 2011Applicant: Eurand Pharmaceuticals LimitedInventors: Luigi Mapelli, Flavio Fabiani, Luigi Boltri, Paolo Gatti, Mauro Serratoni, Roberto Cassanmagnago
-
Publication number: 20110244051Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.Type: ApplicationFiled: April 1, 2011Publication date: October 6, 2011Applicant: THERAVIDA, INC.Inventors: Mehdi PABORJI, Roger S. FLUGEL
-
Patent number: 8021687Abstract: A milnacipran formulation that provides delayed and extended release of milnacipran has been developed. The formulation comprises milnacipran or a salt thereof; an extended release excipient, and a delayed release excipient. The formulation provides, upon administration to a human subject, a Tmax of 4-10 hours.Type: GrantFiled: April 7, 2010Date of Patent: September 20, 2011Assignee: Collegium Pharmaceutical, Inc.Inventors: Jane C. Hirsh, Roman V. Rariy, Shubha Chungi, Srinivas G. Rao, Michael T. Heffernan
-
Publication number: 20110200681Abstract: A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting.Type: ApplicationFiled: April 27, 2011Publication date: August 18, 2011Applicant: CIMA LABS INC.Inventors: Walid Habib, Ehab Hamed, Derek Moe, Carrie Kraling, Lisa Hillman
-
Patent number: 7977369Abstract: Methods for treating bladder cancer comprising intravesicular administration of a stabilized pharmaceutical formulation comprising 5-(1-aziridinyl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methyl-1H-indole-4,7-dione (EO9). More specifically, the stabilized pharmaceutical formulation is instilled in the bladder for a time sufficient to treat the cancer.Type: GrantFiled: March 21, 2008Date of Patent: July 12, 2011Assignee: Spectrum Pharmaceuticals, Inc.Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen
-
Publication number: 20110142933Abstract: A controlled release dosage form of tacrolimus, comprising a solid dispersion of tacrolimus, wherein a controlled release base, which is selected from the group consisting of a water-soluble macromolecule, a gum base, and a membrane forming agent and does not form the solid dispersion of tacrolimus, is further contained, is disclosed. The controlled release dosage form of tacrolimus has an excellent controlled release and shows a stable blood concentration.Type: ApplicationFiled: January 19, 2011Publication date: June 16, 2011Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki KOJIMA, Hiromu KONDO, Keiichi YOSHIHARA, Yuko TAKETANI, Takuya ISHII
-
Publication number: 20110129530Abstract: There is provided a method for preparing a pharmaceutical composition comprising compressible coated, taste-masked and/or controlled-release coated drug-containing particles, rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol, a saccharide, or a mixture thereof, and other optional, pharmaceutically acceptable excipients wherein the orally disintegrating tablet (ODT) or rapidly dispersing tablet (RDT) composition having acceptable tableting, organoleptic, and pharmacokinetic properties.Type: ApplicationFiled: November 30, 2010Publication date: June 2, 2011Applicant: EURAND, INC.Inventors: Gopi M. Venkatesh, Jin-Wang Lai, James M. Clevenger, Craig Kramer
-
Publication number: 20110123635Abstract: The invention relates to an improved process for preparing a new medicament formulation of the active substance dabigatran etexilate of formula I in the form of the methanesulphonic acid salt thereof, and this new medicament formulation as such.Type: ApplicationFiled: July 13, 2009Publication date: May 26, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Guido Bernhard Edmund Radtke
-
Publication number: 20110123613Abstract: Provided are pharmaceutical formulations comprising sustained release particles each having an inner core bead comprising an active pharmaceutical ingredient an intermediate coating substantially surrounding the inner core bead, and an outer coating substantially surrounding the intermediate coating comprising a pH independent polymer. Also provided is a pharmaceutical formulation comprising two bead populations wherein each of the first and second bead populations have a different drug release profile. Also provided is a method of preparing an extended release dosage composition comprising one or more bead populations.Type: ApplicationFiled: December 23, 2010Publication date: May 26, 2011Applicant: MYLAN TECHNOLOGIES INC.Inventors: Pavan Bhat, Sarat C. Chattaraj, Andrew A. Shaw
-
Patent number: 7939105Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.Type: GrantFiled: November 19, 1999Date of Patent: May 10, 2011Assignee: Jagotec AGInventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
-
Patent number: 7939106Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.Type: GrantFiled: May 23, 2003Date of Patent: May 10, 2011Assignee: Jagotec AGInventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
-
Publication number: 20110091537Abstract: The present invention relates to a solid oral pharmaceutical form, with modified release of at least one active ingredient, containing at least microparticles containing said active ingredient and at least one viscosifying agent in a form isolated from said microparticles of active ingredient, characterized in that said microparticles possess an average diameter ranging from 100 to 600 ?m, and are formed by a core containing at least said active ingredient and coated with at least one coating layer, said core being formed by a support particle covered by a layer comprising at least said active ingredient, said coating layer being formed by a material composed of at least 25 to 70% by weight relative to the total weight of said coating, of at least one polymer A insoluble in water, 30 to 75% by weight relative to the total weight of said coating, of at least one polymer B insoluble in water below pH 5 and soluble in water above pH 7, and 0 to 25% by weight relative to the total weight of said coating, of atType: ApplicationFiled: October 15, 2010Publication date: April 21, 2011Applicant: Flamel TechnologiesInventors: Catherine Castan, Anne-Sophie DAVIAUD-VENET
-
Patent number: 7927628Abstract: The present invention provides sustained-release preparations from which a pharmacologically active substance can be released over a long time and a process for producing the same. Such a sustained-release preparation is produced by melt-granulating a low-melting-point substance and a pharmacologically active substance and melt-coating the surface of the thus obtained particles with (1) a fine powder of a water-insoluble polymer or (2) a fine powder of a water-insoluble polymer and at least one member selected from the group consisting of talc, magnesium stearate and titanium oxide.Type: GrantFiled: February 20, 2003Date of Patent: April 19, 2011Assignee: Otsuka Pharmaceutical Co., Ltd.Inventor: Tomohira Yuso
-
Patent number: 7919483Abstract: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.Type: GrantFiled: June 24, 2005Date of Patent: April 5, 2011Assignee: Medicis Pharmaceutical CorporationInventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
-
Publication number: 20110070300Abstract: The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.Type: ApplicationFiled: November 25, 2010Publication date: March 24, 2011Inventors: Prashant Manohar MANDAOGADE, Venkatesh Madhavacharya Joshi, Saurabh Srivastava, Vinayak Dinkar Kadam, Girish Kumar Jain
-
Patent number: 7906475Abstract: Provided are compositions comprising low molecular weight polymeric materials and surfactants having reduced irritation associated therewith, methods of reducing the irritation associated with a personal care composition comprising an anionic and/or amphoteric surfactant, the methods comprising combining a low molecular weight polymeric material capable of binding a surfactant thereto with an anionic surfactant to produce a reduced irritation personal care composition, and methods of using such compositions to cleanse the hair or skin with reduced irritation.Type: GrantFiled: April 27, 2010Date of Patent: March 15, 2011Assignee: Johnson & Johnson Consumer Companies, Inc.Inventors: Russel M. Walters, Michael J. Fevola, Joseph J. Librizzi
-
Publication number: 20110003006Abstract: The present invention is directed to pharmaceutical compositions comprising a plurality of taste-masked non-opioid analgesic/opioid analgesic drug-containing microparticles, dosage forms comprising such pharmaceutical compositions (such as an orally disintegrating tablet), and methods of making the pharmaceutical compositions and dosage forms of the present invention. Dosage forms comprising the pharmaceutical compositions of the present invention are improved homogeneous blends of non-opioid and opioid analgesics which provide for more convenient and palatable administration of drug combinations, for example for treating pain.Type: ApplicationFiled: May 3, 2010Publication date: January 6, 2011Inventors: Gopi Venkatesh, Michael Gosselin, James Clevenger, Jin-Wang Lai
-
Publication number: 20100330150Abstract: The present invention is directed to pharmaceutical compositions comprising a plurality of taste-masked high-dose/low-dose drug-containing microparticles, dosage forms comprising such pharmaceutical compositions (such as an orally disintegrating tablet), and methods of making the pharmaceutical compositions and dosage forms of the present invention. Dosage forms comprising the pharmaceutical compositions of the present invention are improved homogeneous blends of high-dose and low-dose drugs which provide for more convenient and palatable administration of drug combinations, for example for treating pain, hyperglycemia, cardiovascular disease, and allergies.Type: ApplicationFiled: May 3, 2010Publication date: December 30, 2010Inventors: Gopi Venkatesh, Michael Gosselin, James Clevenger, Jin-Wang Lai
-
Publication number: 20100316709Abstract: The present invention provides an orally-disintegrating solid preparation comprising fine granules showing controlled release of a pharmaceutically active ingredient, wherein the outermost layer of the fine granules is coated with a coating layer comprising hydroxypropylmethylcellulose and low-substituted hydroxypropylcellulose and breakage of the fine granules during tableting is suppressed.Type: ApplicationFiled: December 27, 2007Publication date: December 16, 2010Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takashi Kurasawa, Yasuko Watanabe, Yohko Akiyama
-
Publication number: 20100303905Abstract: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.Type: ApplicationFiled: December 1, 2009Publication date: December 2, 2010Inventors: Gopi M. Venkatesh, Nehal H. Vyas, Michael Gosselin, Jin-Wang Lai
-
Patent number: 7838037Abstract: The present invention provides methods for microencapsulation of active ingredients for topical application, whereby double-layer and triple-layer microcapsules are obtained. The microcapsules protect the active ingredients, maintain their original activity throughout processing, formulation and storage, and enable controlled release of the active ingredient only upon application onto the skin.Type: GrantFiled: August 22, 2005Date of Patent: November 23, 2010Assignee: Tagra Biotechnologies Ltd.Inventors: Emma Kvitnitsky, Yury Shapiro, Olga Privalov, Irena Oleinik, Igor Polisher
-
Publication number: 20100278926Abstract: A once a day bupropion salt formulation is disclosed.Type: ApplicationFiled: July 14, 2010Publication date: November 4, 2010Inventors: Boyong Li, Avinash Nangia, Chih Ming Chen, Xiu Xiu Cheng
-
Publication number: 20100266684Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.Type: ApplicationFiled: April 9, 2010Publication date: October 21, 2010Applicant: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Publication number: 20100260842Abstract: Controlled-release pharmaceutical formulations comprising pseudoephedrine or any of its pharmaceutically acceptable salts, processes for preparing the pharmaceutical formulations, and methods of using the formulations.Type: ApplicationFiled: April 6, 2010Publication date: October 14, 2010Inventors: Rashmi Nair, Praveen Raheja, Sanjay Chhagan Wagh, Raviraj Sukumar Pillai
-
Publication number: 20100239667Abstract: Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof.Type: ApplicationFiled: June 4, 2008Publication date: September 23, 2010Applicant: EGALET A/SInventors: Pernille Hoyrup Hemmingsen, Anders Vagno Pedersen, Daniel Bar-Shalom
-
Patent number: 7790705Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.Type: GrantFiled: October 17, 2008Date of Patent: September 7, 2010Assignee: Medicis Pharmaceutical CorporationInventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
-
Publication number: 20100221328Abstract: Described herein are extended-release or sustained-release formulations suitable for highly soluble pharmacologically active compounds, for example, amantadine. Dosage units for providing extended release are provided by the present invention. In some embodiments, the dosage unit comprises a plurality of coated beads having drug layer and a coating layer, wherein the coating layer comprises an ethylcellulose polymer. In some embodiments, near zero-order release of the active compound is achieved.Type: ApplicationFiled: December 30, 2009Publication date: September 2, 2010Inventors: Christian F. Wertz, Victoria Ann O'Neill, Stephen M. Berge
-
Patent number: 7785853Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.Type: GrantFiled: June 26, 2002Date of Patent: August 31, 2010Assignee: Novozymes A/SInventors: Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen